Smith & Nephew PLC
F:NPW1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Smith & Nephew PLC
F:NPW1
|
UK |
|
S
|
Sihuan Pharmaceutical Holdings Group Ltd
OTC:SHPHF
|
CN |
Intrinsic Value
The intrinsic value of 
Smith & Nephew PLC (NPW1) under the Base Case is 11.71 EUR per share.
Compared with the current market price of 13.7 EUR, the stock appears
Overvalued by 14% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Smith & Nephew Does
Smith & Nephew makes medical devices that help doctors repair joints, treat wounds, and perform sports medicine and surgical procedures. Its main products include knee and hip implants, arthroscopy tools, wound care dressings, and equipment used in operating rooms and clinics. The company sells mainly to hospitals, surgeons, and other healthcare providers.
- Headquarters
- United Kingdom UK
- Employees
- 16 988
- IPO date
- Aug 13, 1951
Smith & Nephew has no economic moat
Hospitals and clinicians have alternatives in each of Smith+Nephew’s major product areas, from orthopedic devices and sports medicine to wound care. Its products do not become more useful just because more customers use them, and its markets are not limited to one or two suppliers, leaving rivals room to compete for customers.
Read the full moat analysis
Earnings Waterfall
Smith & Nephew PLC
The intrinsic value for Smith & Nephew PLC (NPW1) under the Base Case is 11.71 EUR.
Compared with the current market price of 13.7 EUR, the stock appears Overvalued by 14% .